These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 3096624)

  • 21. Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function.
    Drusano GL; Weir M; Forrest A; Plaisance K; Emm T; Standiford HC
    Antimicrob Agents Chemother; 1987 Jun; 31(6):860-4. PubMed ID: 3619418
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lead mobilization during calcium disodium ethylenediaminetetraacetate chelation therapy in treatment of chronic lead poisoning.
    Sánchez-Fructuoso AI; Cano M; Arroyo M; Fernández C; Prats D; Barrientos A
    Am J Kidney Dis; 2002 Jul; 40(1):51-8. PubMed ID: 12087561
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of renal impairment on disposition of pentopril and its active metabolite.
    Rakhit A; Radensky P; Szerlip HM; Kochak GM; Audet PR; Hurley ME; Feldman GM
    Clin Pharmacol Ther; 1988 Jul; 44(1):39-48. PubMed ID: 3391004
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cefsulodin pharmacokinetics in patients with various degrees of renal function.
    Matzke GR; Keane WF
    Antimicrob Agents Chemother; 1983 Mar; 23(3):369-73. PubMed ID: 6847169
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mobilizable lead in patients with chronic renal failure.
    Koster J; Erhardt A; Stoeppler M; Mohl C; Ritz E
    Eur J Clin Invest; 1989 Apr; 19(2):228-33. PubMed ID: 2499482
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Occult lead intoxication as a cause of hypertension and renal failure.
    Sánchez-Fructuoso AI; Torralbo A; Arroyo M; Luque M; Ruilope LM; Santos JL; Cruceyra A; Barrientos A
    Nephrol Dial Transplant; 1996 Sep; 11(9):1775-80. PubMed ID: 8918621
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Body burdens of lead in hypertensive nephropathy.
    Osterloh JD; Selby JV; Bernard BP; Becker CE; Menke DJ; Tepper E; Ordonez JD; Behrens B
    Arch Environ Health; 1989; 44(5):304-10. PubMed ID: 2510613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lead exposure and renal failure: does renal insufficiency influence lead kinetics?
    Campbell BC; Elliott HL; Meredith PA
    Toxicol Lett; 1981 Oct; 9(2):121-4. PubMed ID: 7302983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is the volume of distribution of digoxin reduced in patients with renal dysfunction? Determining digoxin pharmacokinetics by fluorescence polarization immunoassay.
    Cheng JW; Charland SL; Shaw LM; Kobrin S; Goldfarb S; Stanek EJ; Spinler SA
    Pharmacotherapy; 1997; 17(3):584-90. PubMed ID: 9165563
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Urinary lead excretion in uremic patients.
    Behringer D; Craswell P; Mohl C; Stoeppler M; Ritz E
    Nephron; 1986; 42(4):323-9. PubMed ID: 3083277
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Environmental lead exposure and progression of chronic renal diseases in patients without diabetes.
    Lin JL; Lin-Tan DT; Hsu KH; Yu CC
    N Engl J Med; 2003 Jan; 348(4):277-86. PubMed ID: 12540640
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of thiamine and EDTA on biliary and urinary lead excretion in sheep.
    Olkowski AA; Gooneratne SR; Christensen DA
    Toxicol Lett; 1991 Dec; 59(1-3):153-9. PubMed ID: 1755021
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Purine metabolism in patients with gout: the role of lead.
    Miranda-Carús E; Mateos FA; Sanz AG; Herrero E; Ramos T; Puig JG
    Nephron; 1997; 75(3):327-35. PubMed ID: 9069456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The influence of renal function on the renal clearance of morphine and its glucuronide metabolites in intensive-care patients.
    Milne RW; Nation RL; Somogyi AA; Bochner F; Griggs WM
    Br J Clin Pharmacol; 1992 Jul; 34(1):53-9. PubMed ID: 1633068
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of hyperparathyroidism on blood lead concentrations in man.
    Osterloh JD; Clark OH
    Environ Res; 1993 Jul; 62(1):1-6. PubMed ID: 8325255
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Compared effects of high oral Mg supplements and of EDTA chelating agent on chronic lead intoxication in rabbits.
    Soldatovic D; Vujanovic D; Matovic V; Plamenac Z
    Magnes Res; 1997 Jun; 10(2):127-33. PubMed ID: 9368233
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective evaluation of ten methods for estimating creatinine clearance in children with varying degrees of renal dysfunction.
    Paap CM; Nahata MC
    J Clin Pharm Ther; 1995 Apr; 20(2):67-73. PubMed ID: 7650077
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Moderate lead poisoning: trends in blood lead levels in unchelated children.
    Markowitz ME; Bijur PE; Ruff HA; Balbi K; Rosen JF
    Environ Health Perspect; 1996 Sep; 104(9):968-72. PubMed ID: 8899376
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of beta-methyldigoxin in subjects with normal and impaired renal function.
    Tsutsumi K; Nakashima H; Tateishi T; Imagawa M; Nakano S
    J Clin Pharmacol; 1993 Feb; 33(2):154-60. PubMed ID: 8440765
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elimination kinetics of mezlocillin in normal and impaired renal function including the effects of dialysis.
    Kosmidis J; Doundoulaki P; Stathakis C; Zerefos N; Bounia A; Daikos GK
    Arzneimittelforschung; 1979; 29(12a):1960-2. PubMed ID: 543901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.